Efficacy and safety of sultamicillin (750 mg bid) compared with amoxycillin/clavulanate (625 mg tid) in patients with uncomplicated urinary tract infections

International Journal of Antimicrobial Agents

Volumn 6, Issue SUPPL.1, 1996, Pages

  Schutz W ^a  

^a Urological Hospital   (Germany)

Author keywords

Amoxycillin clavulanic acid; Sultamicillin; Urinary tract infections; Lactamase inhibitors

Indexed keywords

EID: 4243591739     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-8579(96)80009-4     Document Type: Article

References (18)

1. Simon C, Stille W. Infektionen des Urogenitaltraktes. In: Simon C, Stille W (eds) Antibiotika Therapie in Klinik und Praxis, 7. Aufl. Schattauer, Stuttgart, 1989, pp. 454-461.
2. Naber KG, Wittenberger R. Sultamicillin versus trimethoprim/sulfamethoxazole in the treatment of urinary tract infections. APMIS 1989(suppl. 5):57-62.
3. Neu HC. The emergence of bacterial resistance and its influences on empiric therapy. Rev Inf Dis 1983;5(suppl. 1):S9-S20.
4. Williams ID. Importance of β-lactamases and clinical implications of their inhibitors. Drugs 1988;35(suppl. 7):3-11.
5. English AR, Retsema JA, Girard AE et al. CP 45,899, a β-lactamase inhibitor that extends the antibacterial spectrum of β-lactams: initial bacteriological characterization. Antimicrob Agents Chemother 1978;14:414-419.
6. Grimm H. The in vitro activity of sulbactam/ampicillin. In: Ueda Y, Neu HC (eds) β-Lactamase blocking agents. In: Proc. Workshop 14th Int Congr Chemotherapy, Kyoto, 1985. University of Tokyo Press, Tokyo, 1986.
7. Heizmann W, Heilman F, Werner H. In vitro activity of ampicillin plus sulbactam against anaerobes compared to ampicillin and cefoxitin. Infection 1987;15:370-347.
8. Klietmann W, Nösner KL, Focht J. Antibakterielle Wirksamkeit der Kombination Sulbactam/Ampicillin im Vergleich mit Amoxicillin/Clavulansäure und Ampicillin. Z Antimikrob Chemother 1987;5:79-84.
9. Lees L, Milson JA, Knirsch AK, Greenhalg K. Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use. Rev Infect Dis 1986;8(suppl. 5):644-650.
10. Retsema JA, English AR, Girard AE et al. Sulbactam and ampicillin synergistic anti-bacterial activity against hospital isolates of Enterobacteriaceae, methicillin-resistant Staphylococcus and anaerobes. In: Proc 13th Int Congr Chemotherapy, Vienna, 1983, pp. 23/1-23/5.
11. Aswapokee N, Neu HC. A sulfone β-lactam compound which acts as a β-lactamase inhibitor. J Antibiot (Tokyo) 1978;31:1238-1244.
12. Foulds G, Brennan DR. Some aspects of the absorption of sultamicillin. Abstract 515, 22nd Intersci Conf Antimicrobial Agents and Chemotherapy, Miami Beach, FL, 4-6 October 1982.
13. Foulds G, Stankewich JP, Knirsch AK, Weidler DJ. The pharmacokinetics of sultamicillin in man. Abstract 519, 22nd Intersci Conf Antimicrobial Agents and Chemotherapy, Miami Beach, FL, 4-6 October 1982.
14. Hampel B, Lode H, Bruckner G, Koeppe P. Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers. Drugs 1988;35(suppl. 7):29-33.
15. Hartley S, Wise R. A three-way crossover study to compare the pharmacokinetics and acceptability of sultamicillin at two dose levels with that of ampicillin. J Antimicrob Chemother 1982;10:49-55.
16. Friedel HA, Campoli-Richards DM, Goa KL. Sultamicillin - a review of its antibacterial activity, pharmocokinetic properties and therapeutic use. Drugs 1989;37:491-522.
17. Weißer J, Wesch R, Kresken M. Clinical experience with augmentin in German hospitals. Abstract 241, 2nd Biennial Conf Chemotherapy of Infectious Disease. Paul-Ehrlich-Gesellschaft für Chemotherapie. Z Antimikrob Chemother 1989(suppl. 1).
18. Abbas AMA, Goel PK, Venkit N, Gowers E. Augmentin therapy in the treatment of urinary tract infections in general practice. Br J Clin Pract 1984;38:2.